Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009

Glioblastoma in England: 2007–2011

(2015) Andrew Brodbelt et al.   EUROPEAN JOURNAL OF CANCER

Patient and treatment factors associated with survival among adult glioblastoma patients: A USA population-based study from 2000–2010

(2015) I-Wen Pan et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Brain tumors in Sweden: Data from a population-based registry 1999–2012

(2014) Thomas Asklund et al.   ACTA ONCOLOGICA

Population-based survival analyses of central nervous system tumors from 1994 to 2008. An up-dated study in the temozolomide-era

(2014) Rafael Fuentes-Raspall et al.   Cancer Epidemiology

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

(2014) Michael Weller et al.   LANCET ONCOLOGY

Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma

(2013) Terri S. Armstrong et al.   JOURNAL OF CLINICAL ONCOLOGY

A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme

(2012) Pål A. Rønning et al.   NEURO-ONCOLOGY

Improved survival time trends for glioblastoma using the SEER 17 population-based registries

(2011) Matthew Koshy et al.   JOURNAL OF NEURO-ONCOLOGY

Glioblastoma survival in the United States before and during the temozolomide era

(2011) Derek R. Johnson et al.   JOURNAL OF NEURO-ONCOLOGY

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

Age as a Predictive Factor in Glioblastomas: Population-Based Study

(2009) Daisuke Kita et al.   NEUROEPIDEMIOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study

(2008) Izabela Zawlik et al.   NEUROEPIDEMIOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE